Literature DB >> 7800782

Antibiotic therapy for Lyme disease in Maryland.

G T Strickland1, I Caisley, M Woubeshet, E Israel.   

Abstract

The recommended treatment of Lyme disease is evolving and important questions remain unanswered, such as (a) Are inexpensive oral regimens effective in curing acute illness and preventing arthritic, neurologic, and cardiac manifestations or are much more costly, and potentially toxic, intravenous antibiotics required? (b) Are relatively short 2- to 3-week courses of antibiotics sufficient or are prolonged regimens of a month, or more, better? This study reviews antibiotic therapy prescribed by Maryland physicians for the 283 cases reported in 1991 that meet the Centers for Disease Control and Prevention's case definition for Lyme disease. The purpose of the review was to obtain baseline information on the antibiotics being used by physicians in practice to treat patients that they believe have Lyme disease. The most frequently prescribed antibiotics for either the 60 percent of patients presenting with erythema migrans or the 40 percent with arthritic, neurologic, or cardiac manifestations were oral doxycycline (47 percent), tetracycline (11 percent), and amoxicillin (13 percent). Seventy-one percent of therapeutic courses were for 2 to 3 weeks. Amoxicillin was used in two-thirds of children younger than 8 years. Sixty (21 percent) received intravenous therapy, of which ceftriaxone, with or without other antibiotics, was almost always (95 percent) used. Intravenous therapy was more frequently given to those with arthritic, neurologic, and cardiac manifestations than to those with erythema migrans (odds ratio = 3.7) and to those with these systemic symptoms along with erythema migrans than to those with erythema migrans alone (odds ratio = 3.8). The average course was 2 days longer in treating those with arthritic, neurologic, or cardiac manifestations than in treating those with erythema migrans alone(P = 0.05).An epidemiologic assessment of antibiotics prescribed by the physicians in Maryland to treat Lyme disease in 1991 shows the choices, dosage, and duration of drugs generally followed those most frequently recommended in the literature. Also, it shows that efforts to educate physicians should be directed more towards the diagnosis rather than the treatment of Lyme disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7800782      PMCID: PMC1403575     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  10 in total

1.  Lyme disease in Maryland: 1987-1990.

Authors:  C S Mitchell; M Cloeren; E Israel; C Lazar; B S Schwartz
Journal:  Md Med J       Date:  1992-05

Review 2.  Lyme disease: recommendations for diagnosis and treatment.

Authors:  D W Rahn; S E Malawista
Journal:  Ann Intern Med       Date:  1991-03-15       Impact factor: 25.391

Review 3.  Biology of Borrelia species.

Authors:  A G Barbour; S F Hayes
Journal:  Microbiol Rev       Date:  1986-12

4.  Summary of the first 100 patients seen at a Lyme disease referral center.

Authors:  L H Sigal
Journal:  Am J Med       Date:  1990-06       Impact factor: 4.965

5.  Empiric parenteral antibiotic treatment of patients with fibromyalgia and fatigue and a positive serologic result for Lyme disease. A cost-effectiveness analysis.

Authors:  R W Lightfoot; B J Luft; D W Rahn; A C Steere; L H Sigal; D C Zoschke; P Gardner; M C Britton; R L Kaufman
Journal:  Ann Intern Med       Date:  1993-09-15       Impact factor: 25.391

6.  Lyme arthritis as the incorrect diagnosis in pediatric and adolescent fibromyalgia.

Authors:  L H Sigal; S J Patella
Journal:  Pediatrics       Date:  1992-10       Impact factor: 7.124

7.  The overdiagnosis of Lyme disease.

Authors:  A C Steere; E Taylor; G L McHugh; E L Logigian
Journal:  JAMA       Date:  1993-04-14       Impact factor: 56.272

8.  A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites.

Authors:  E D Shapiro; M A Gerber; N B Holabird; A T Berg; H M Feder; G L Bell; P N Rys; D H Persing
Journal:  N Engl J Med       Date:  1992-12-17       Impact factor: 91.245

9.  Treatment of early Lyme disease.

Authors:  E M Massarotti; S W Luger; D W Rahn; R P Messner; J B Wong; R C Johnson; A C Steere
Journal:  Am J Med       Date:  1992-04       Impact factor: 4.965

10.  Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis.

Authors:  R J Dattwyler; D J Volkman; S M Conaty; S P Platkin; B J Luft
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

  10 in total
  4 in total

Review 1.  Physician preferences in the diagnosis and treatment of Lyme disease in the United States.

Authors:  M H Ziska; S T Donta; F C Demarest
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

2.  U.S. healthcare providers' experience with Lyme and other tick-borne diseases.

Authors:  Meghan E Brett; Alison F Hinckley; Emily C Zielinski-Gutierrez; Paul S Mead
Journal:  Ticks Tick Borne Dis       Date:  2014-04-06       Impact factor: 3.744

3.  Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014-2016.

Authors:  Sarah A Hook; Seonghye Jeon; Sara A Niesobecki; AmberJean P Hansen; James I Meek; Jenna K H Bjork; Franny M Dorr; Heather J Rutz; Katherine A Feldman; Jennifer L White; P Bryon Backenson; Manjunath B Shankar; Martin I Meltzer; Alison F Hinckley
Journal:  Emerg Infect Dis       Date:  2022-06       Impact factor: 16.126

4.  Borreliacidal activity of Borrelia metal transporter A (BmtA) binding small molecules by manganese transport inhibition.

Authors:  Dhananjay Wagh; Venkata Raveendra Pothineni; Mohammed Inayathullah; Song Liu; Kwang-Min Kim; Jayakumar Rajadas
Journal:  Drug Des Devel Ther       Date:  2015-02-11       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.